Admin-Core-001

管理核心-001

• 批准号: 10707766
• 负责人: TIMOTHY P CRIPE
• 金额: $ 22.58万
• 依托单位: RESEARCH INST NATIONWIDE CHILDREN'S HOSP
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-18 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10707766
• 关键词: Admin; Core; 001

This application describes the Pediatric Ohio-New York Cancer (Peds-ONC) Immunotherapy Center, created in response to the RFA as a second nidus for the Pediatric Immunotherapy Discovery and Development Consortium (PI-DDN). To complement the funded U54 (Maris and Mackall, MPI) of the PI-DDN that largely seeks to harness adaptive immunity to further develop CAR-T cells against newly identified antigens, we propose to harness innate immunity to target pediatric cancers, to circumvent resistance to conventional therapy, and to further enable adaptive/hybrid immune approaches

该申请描述了儿科俄亥俄-纽约癌症（pedd - onc）免疫治疗中心，该中心是根据RFA作为儿科免疫治疗发现和发展联盟（PI-DDN）的第二个中心而创建的。为了补充资助的PI-DDN的U54 (Maris和Mackall， MPI)，该项目主要寻求利用适应性免疫来进一步开发针对新鉴定抗原的CAR-T细胞，我们建议利用先天免疫来靶向儿科癌症，规避对常规治疗的抵抗，并进一步实现适应性/混合免疫方法